Tests cytarabine with venetoclax after treatment in older adults with acute myeloid leukemia
Tests medium-dose cytarabine with venetoclax in older adults with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Key facts
- Where
- Changchun, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 60 to 75 with acute myeloid leukemia at intermediate or high risk. They must be in remission after first treatment and unable to have a stem cell transplant from a donor.
- Age
- 60 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia (not acute promyelocytic leukemia), intermediate or high risk by ELN (2022). Remission after induction therapy, with no leukemia seen in the bone marrow.
- Earlier treatment
- Must have had induction therapy and reached remission. Must not have had another clinical trial in the last 30 days. Must not be able to have a stem cell transplant from a donor.
Main reasons for not taking part
- Allergy to a trial drug or a similar drug
- Cannot tolerate chemotherapy (Ferrara 2013 criteria)
- Relapse with more than 5% blasts or immature cells in the bone marrow
- Serious liver, kidney or heart problems
- Active infection or another cancer needing treatment
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 75 years old?
Source: NCT06990321, who can take part
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaContact: Yehui TanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yehui Tan
- Trial code
- NCT06990321
- Record updated
- 8 August 2025
- Original description
A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the ElderlyRead full original descriptionShow less
A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination With Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in The Elderly
A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly
Inclusion: 1.Age ≥ 60 years and ≤ 75 years, regardless of gender; 2.Diagnosed with AML (acute myeloid leukemia) according to WHO criteria (non-acute promyelocytic leukemia); 3.Risk stratification as intermediate or high risk based on the ELN (2022) guidelines; 4.Expected survival time ≥ 3 months; 5.Not suitable for allogeneic hematopoietic stem cell transplantation; 6.AML patients who achieve remission with morphologic assessment of bone marrow showing no leukemic involvement after induction therapy; 7.Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2; 8.Meeting the following laboratory requirements (performed within 7 days prior to treatment):; Total bilirubin ≤ 1.5 times the upper limit of normal for the same age group; AST and ALT ≤ 2.5 times the upper limit of normal for the same age group; Serum creatinine \< 2 times the upper limit of normal for the same age group; Cardiac ejection fraction within normal limits as determined by echocardiogram. 9.Able to comply with the study visit schedule and understand and adhere to all trial protocol requirements; 10.Able to take oral medications.
Exclusion: Allergic to any drugs included in the trial protocol or drugs with a chemical structure similar to the investigational drug; Chemotherapy intolerance assessed by Ferrara 2013 criteria prior to enrollment; Known or suspected drug abuse or alcohol dependence; History of uncontrolled or symptomatic angina. 2) Myocardial infarction within 6 months prior to enrollment. 3) History of arrhythmias requiring drug treatment or with severe clinical symptoms; Simultaneous diagnosis of other malignant tumors in organs (requiring treatment); Mental illness or any condition that prevents obtaining informed consent, or inability to comply with the study treatment and examination requirements; Active heart disease, defined as one or more of the following:; Liver dysfunction (total bilirubin \>1.5×ULN, ALT/AST \>2.5×ULN, or liver-involved patients with ALT/AST \>5×ULN), kidney dysfunction (serum creatinine \>1.5×ULN); Uncontrolled or symptomatic congestive heart failure (\>NYHA class 2). 5) Ejection fraction below the lower limit of normal. 9.Participation in another clinical trial within 30 days. 10.Active infection. 11.The investigator deems the subject unfit for participation in this trial; Subjects who meet any of the following criteria shall not be included in this study:; Hematologic relapse (bone marrow blasts or immature cells exceed 5%).